Time course of antiproteinuric effect of aliskiren in arterial hypertension associated with type 2 diabetes and microalbuminuria

Expert Opinion on Pharmacotherapy

Volumn 14, Issue 4, 2013, Pages 371-384

  Fogari, Roberto ^a   Mugellini, Amedeo ^a   Zoppi, Annalisa ^a   Preti, Paola ^a   Maffioli, Pamela ^a   Perrone, Tiziano ^a   Derosa, Giuseppe ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

Aldosterone; Aliskiren; Hypertension; Microalbuminuria; Ramipril

Indexed keywords

ALBUMIN; ALDOSTERONE; ALISKIREN; AMLODIPINE; CREATININE; POTASSIUM; RAMIPRIL;

ADD ON THERAPY; ADULT; AGED; ALDOSTERONE BLOOD LEVEL; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE MONITORING; CONTROLLED STUDY; COUGHING; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPERKALEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PARALLEL DESIGN; POTASSIUM BLOOD LEVEL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIDE EFFECT; STATISTICAL SIGNIFICANCE; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; URINARY EXCRETION;

ADULT; AGED; ALBUMINS; ALBUMINURIA; ALDOSTERONE; AMIDES; ANTIHYPERTENSIVE AGENTS; ARTERIAL PRESSURE; BIOLOGICAL MARKERS; BLOOD PRESSURE MONITORING, AMBULATORY; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FUMARATES; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RAMIPRIL; RENIN; SINGLE-BLIND METHOD; TREATMENT OUTCOME;

EID: 84874492623     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2013.772981     Document Type: Article

References (52)

1. Ritz E, Dikow R. Hypertension and antihypertensive treatment of diabetic nephropathy. Nat Clin Pract Nephrol 2006;2(10):562-7
2. Yamagishi S, Fukami K, Ueda S, Okuda S. Molecular mechanisms of diabetic nephropathy and its therapeutic intervention. Curr Drug Targets 2007;8(8):952-9
3. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993;329(20):1456-62
4. The EUCLID Study Group. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet 1997;349(9068):1787-92
5. Brenner BM, Cooper ME, de Zeeuw D, et al. RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345(12):861-9
6. Lewis EJ, Hunsicker LG, Clarke WR, et al. Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345(12):851-60
7. Parving HH, Lehnert H, Brochner-Mortensen J, et al. Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345(12):870-8
8. Haller H, Ito S, Izzo JL Jr, et al. ROADMAP Trial Investigators. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med 2011;364(10):907-17
9. Rossing P, Hommel E, Smidt UM, Parving HH. Reduction in albuminuria predicts a beneficial effect on diminishing the progression of human diabetic nephropathy during antihypertensive treatment. Diabetologia 1994;37(5):511-16
10. de Zeeuw D, Remuzzi G, Parving HH, et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int 2004;65(6):2309-20
11. Gerstein HC, Mann JF, Yi Q, et al. HOPE Study Investigators. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001;286(4):421-6
12. Lambers Heerspink HJ, Brinkman JW, Bakker SJ, et al. Update on microalbuminuria as a biomarker in renal and cardiovascular disease. Curr Opin Nephrol Hypertens 2006;15(6):631-6
13. Jafar TH, Schmid CH, Landa M, et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med 2001;135(2):73-87
14. Suissa S, Hutchinson T, Brophy JM, Kezouh A. ACE-inhibitor use and the long-term risk of renal failure in diabetes. Kidney Int 2006;69(5):913-19
15. Keilani T, Danesh FR, Schlueter WA, et al. A subdepressor low dose of ramipril lowers urinary protein excretion without increasing plasma potassium. Am J Kidney Dis 1999;33(3):450-7
16. Ruggenenti P, Mosconi L, Sangalli F, et al. Glomerular size-selective dysfunction in NIDDM is not ameliorated by ACE inhibition or by calcium channel blockade. Kidney Int 1999;55(3):984-94
17. Jensen C, Herold P, Brunner HR. Aliskiren: the first renin inhibitor for clinical treatment. Nat Rev Drug Discov 2008;7(5):399-410
18. Riccioni G. Aliskiren in the treatment of hypertension and organ damage. Cardiovasc Ther 2011;29(1):77-87
19. Persson F, Rossing P, Schjoedt KJ, et al. Time course of the antiproteinuric and antihypertensive effects of direct renin inhibition in type 2 diabetes. Kidney Int 2008;73(12):1419-25
20. Parving HH, Persson F, Lewis JB, et al. AVOID Study Investigators. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008;358(23):2433-46
21. Groppelli A, Omboni S, Ravogli A, et al. Validation of the SpaceLabs 90202 and 90207 devices for ambulatory blood pressure monitoring by comparison with intra-arterial resting and ambulatory measurements. J Hypertens Suppl 1991;9(6):S334-5
22. Parati G, Bosi S, Castellano M, et al. Guidelines for 24-h non-invasive ambulatory blood pressure monitoring: report from a working group of the Italian Society of Hypertension. High Blood Press 1995;4:168-74
23. Uresin Y, Taylor AA, Kilo C, et al. Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension. J Renin Angiotensin Aldosterone Syst 2007;8(4):190-8
24. Andersen K, Weinberger MH, Egan B, et al. Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial. J Hypertens 2008;26(3):589-99
25. Weber MA, Julius S, Kjeldsen SE, et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet 2004;363(9426):2049-51
26. Dahlof B, Sever PS, Poulter NR, et al. ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005;366(9489):895-906
27. Bramley TJ, Gerbino PP, Nightengale BS, Frech-Tamas F. Relationship of blood pressure control to adherence with antihypertensive monotherapy in 13 managed care organizations. J Manag Care Pharm 2006;12(3):239-45
28. Andersen K, Weinberger MH, Constance CM, et al. Comparative effects of aliskiren-based and ramipril-based therapy on the renin system during long-term (6 months) treatment and withdrawal in patients with hypertension. J Renin Angiotensin Aldosterone Syst 2009;10(3):157-67
29. Zhao C, Vaidyanathan S, Yeh CM, et al. Aliskiren exhibits similar pharmacokinetics in healthy volunteers and patients with type 2 diabetes mellitus. Clin Pharmacokinet 2006;45(11):1125-34
30. Meisel S, Shamiss A, Rosenthal T. Clinical pharmacokinetics of ramipril. Clin Pharmacokinet 1994;26(1):7-15
31. Vrijens B, Vincze G, Kristanto P, et al. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ 2008;336(7653):1114-17
32. Imanishi M, Yoshioka K, Konishi Y, et al. Glomerular hypertension as one cause of albuminuria in type II diabetic patients. Diabetologia 1999;42(8):999-1005
33. Andersen S, Blouch K, Bialek J, et al. Glomerular permselectivity in early stages of overt diabetic nephropathy. Kidney Int 2000;58(5):2129-37
34. Bonnet F, Cooper ME, Kawachi H, et al. Irbesartan normalises the deficiency in glomerular nephrin expression in a model of diabetes and hypertension. Diabetologia 2001;44(7):874-7
35. Langham RG, Kelly DJ, Cox AJ, et al. Proteinuria and the expression of the podocyte slit diaphragm protein, nephrin, in diabetic nephropathy: effects of angiotensin converting enzyme inhibition. Diabetologia 2002;45(11):1572-6
36. Jan Danser AH, Batenburg WW, van Esch JH. Prorenin and the (pro) renin receptor-an update. Nephrol Dial Transplant 2007;22(5):1288-92
37. Phillips LM, Wang Y, Dai T, et al. The renin inhibitor aliskiren attenuates high-glucose induced extracellular matrix synthesis and prevents apoptosis in cultured podocytes. Nephron Exp Nephrol 2011;118(3):e49-59
38. Nguyen G, Contrepas A, Mueller DN, et al. Effect of the direct renin inhibitor aliskiren on (pro)renin receptor and profibrotic gene expression in kidneys of diabetic TG(mRen-2)27 rats. J Am Soc Nephrol 2007;18:60A
39. Feldman DL, Jin L, Xuan H, et al. Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mRen-2) 27 rats. Hypertension 2008;52(1):130-6
40. Kelly DJ, Zhang Y, Moe G, et al. Aliskiren, a novel renin inhibitor, is renoprotective in a model of advanced diabetic nephropathy in rats. Diabetologia 2007;50(11):2398-404
41. Nguyen G. Increased cyclooxygenase-2, hyperfiltration, glomerulosclerosis, and diabetic nephropathy: put the blame on the (pro)renin receptor? Kidney Int 2006;70(4):618-20
42. Fisher ND, Jan Danser AH, Nussberger J, et al. Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humans. Circulation 2008;117(25):3199-205
43. Cherney DZ, Lai V, Scholey JW, et al. Effect of direct renin inhibition on renal hemodynamic function, arterial stiffness, and endothelial function in humans with uncomplicated type 1 diabetes: a pilot study. Diabetes Care 2010;33(2):361-5
44. Hollenberg NK, Price DA, Fisher ND, et al. Glomerular hemodynamics and the renin-angiotensin system in patients with type 1 diabetes mellitus. Kidney Int 2003;63(1):172-8
45. Feldman DL. New insights into the renoprotective actions of the renin inhibitor aliskiren in experimental renal disease. Hypertens Res 2010;33(4):279-87
46. Ogawa S, Nako K, Okamura M, et al. Aliskiren reduces albuminuria and oxidative stress, and elevates glomerular filtration rates in Japanese patients with advanced diabetic nephropathy. Hypertens Res 2011;34(3):400-1
47. Ogawa S, Kobori H, Ohashi N, et al. Angiotensin II type 1 receptor blockers reduce urinary angiotensinogen excretion and the levels of urinary markers of oxidative stress and inflammation in patients with type 2 diabetic nephropathy. Biomark Insights 2009;4:97-102
48. Fredersdorf S, Endemann DH, Luchner A, et al. Increased aldosterone levels in a model of type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 2009;117(1):15-20
49. Epstein M. Aldosterone and the hypertensive kidney: its emerging role asa mediator of progressive renal dysfunction: a paradigm shift. J Hypertens 2001;19(5):829-42
50. Blasi ER, Rocha R, Rudolph AE, et al. Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int 2003;63(5):1791-800
51. Sato A, Saruta T. Aldosterone breakthrough during angiotensin-converting enzyme inhibitor therapy. Am J Hypertens 2003;16(9 Pt 1):781-8
52. Parving HH, Brenner BM, McMurray JJ, et al. For the ALTITUDE Investigators. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012;367:2204-13